

HOLD TP: Rs 699 | △ 14%

**MARICO** 

Consumer Staples

08 July 2024

# **Business update: Distributor response to Project SETU**

- Marico noted continued improving demand trend with likely further acceleration through FY25. Volume trend improved despite destocking
- Despite a medium to long-term positive for Marico, Project SETU implies sales cannibalisation between channels
- Indirect channel destocking may continue and remain a drag on rural recovery over the next 2-3 quarters. Retain HOLD

Lokesh Gusain research@bobcaps.in

**1QFY25 business update:** MRCO issued its 1QFY25 business update last week on Friday after market close. Sales were up in High-Speed Digits (HSD) with operating profit growth slightly ahead of sales. MRCO's FY25 outlook is for sales growth to accelerate further during the year on improving demand in the domestic market and favourable pricing.

**Positives:** (1) Sequential demand improved reflecting slight improvement in volume growth post distributor destocking. Parachute up in low single digits and Saffola up in mid-single digits. (2) Gross margins to improve on favourable mix – copra prices in line with forecasts, while edible oil and crude oil derivatives remained rangebound.

**Negatives:** (1) Value Added Hair Oil (VAHO) volumes remained negative with continued pressures in the Bottom of The Pyramid (BoP) segment, even as the mid and premium fared better. (2) Distributor destocking negatively impacted volumes. (3) Operating profit growth to be only slightly ahead of revenue growth despite gross margin expansion given business reinvestments.

**FY25 outlook:** Consolidated revenue growth to accelerate through the year on improving volume trend and higher price realisation on favourable pricing cycle. The 1QFY25 sales run rate is at high single digits. For FY25, we are at sales of +10% (Bloomberg consensus at +10%) and EBITDA of +11% (consensus +14%).

Valuation and our view: We value MRCO based on P/E relative to the NIFTY 50 index and apply a 10% premium. We use 51x FY26E P/E to derive the TP of Rs 699. Project SETU is aimed at increasing direct reach by 50% by FY27. In our view, the distributor reaction is natural given sales cannibalisation – destocking remains a risk over the next two to three quarters. While rural recovery may reflect in consumer offtake, we expect both margin and inventory stocking pressure on MRCO from the indirect channel. We maintain our HOLD rating.

## Key changes

•	U		
	Target	Rating	
	< ▶	< ▶	

Ticker/Price	MRCO IN/Rs 615
Market cap	US\$ 9.7bn
Free float	40%
3M ADV	US\$ 23.9mn
52wk high/low	Rs 667/Rs 486
Promoter/FPI/DII	59%/25%/16%

Source: NSE | Price as of 5 Jul 2024

#### **Key financials**

FY24A	FY25E	FY26E
96,530	106,242	116,640
20,260	22,471	24,229
14,810	16,281	17,679
11.5	12.6	13.7
11.5	12.9	14.4
36.5	37.1	36.6
53.6	48.8	44.9
39.2	35.3	32.8
13.7	9.9	8.6
	96,530 20,260 14,810 11.5 11.5 36.5 53.6 39.2	96,530 106,242 20,260 22,471 14,810 16,281 11.5 12.6 11.5 12.9 36.5 37.1 53.6 48.8 39.2 35.3

Source: Company, Bloomberg, BOBCAPS Research | P - Provisional

#### Stock performance



Source: NSE





# **Financials**

Y/E 31 Mar (Rs mn)	FY22A	FY23A	FY24A	FY25E	FY26E
Total revenue	95,120	97,640	96,530	106,242	116,640
EBITDA	16,810	18,100	20,260	22,471	24,229
Depreciation	1,390	1,550	1,580	1,894	1,894
EBIT	15,420	16,550	18,680	20,577	22,336
Net interest inc./(exp.)	390	560	730	652	652
Other inc./(exp.)	980	1,440	1,420	1,491	1,566
Exceptional items	0	0	0	0	1,000
EBT	16,010	17,430	19,370	21,417	23,250
Income taxes	3,460	4,210	4,350	4,926	5,347
Extraordinary items	0,400	7,210	0	0	0,047
Min. int./Inc. from assoc.	300	200	210	210	223
Reported net profit	12,250	13.020	14,810	16,281	17,679
Adjustments	0	0	0	0	0
Adjusted net profit	12,250	13,020	14,810	16,281	17,679
Adjusted net pront	12,200	10,020	14,010	10,201	11,010
Balance Sheet					
Y/E 31 Mar (Rs mn)	FY22A	FY23A	FY24A	FY25E	FY26E
Accounts payables	13,440	14,520	15,810	14,148	15,505
Other current liabilities	2.240	2,170	2,110	2.322	2,550
Provisions	220	480	80	81	82
Debt funds	3,450	4,750	3,830	3,830	3,830
Other liabilities	4,460	7,980	10,690	11,457	12,277
Equity capital	1,290	1,290	1,290	1,290	1,290
Reserves & surplus	32,760	38,270	40,400	44,680	49,323
Shareholders' fund	34,050	39,560	41,690	45,970	50,613
Total liab. and equities	57,860	69,460	74,210	77,808	84,857
Cash and cash eq.	5,790	7,560	9,430	8,567	11,193
Accounts receivables	6,520	10,150	10,690	12,225	13,422
Inventories	14,120	12,250	13,360	15,005	16,444
Other current assets	2,210	2,460	3,960	4,350	4,768
Investments	8,280	10,960	6,020	6,365	6,735
Net fixed assets	6,000	6,330	7,000	7,042	7,720
CWIP	390	670	440	440	440
				9,370	
Intangible assets Deferred tax assets, net	3,060 1,870	5,600 1,460	9,370 680	748	9,370 822
Other assets Total assets	9,620	12,020	13,260	13,500	13,758
Total assets	57,860	69,460	74,210	77,614	84,673
Cash Flows					
Y/E 31 Mar (Rs mn)	FY22A	FY23A	FY24A	FY25E	FY26E
Cash flow from operations		14,190			19,822
Capital expenditures	10,160		14,360	15,000	
<u> </u>	(1,320)	(1,820)	(1,530) 1,480	(2,656)	(2,916)
Change in investments	3,370	(3,890)		•	
Other investing cash flows	2,200	(2,940)	1,810	(345)	(369)
Cash flow from investing	4,250	(8,650)	1,760	(3,001)	(3,285)
Equities issued/Others	410	90	(010)	0	0
Debt raised/repaid	(30)	1,280	(910)	(653)	(650)
Interest expenses	(280)	(420)	(540)	(652)	(652)
Dividends paid	(12,170)	(6,070)	(12,290)	(12,211)	(13,259)
Other financing cash flows	(830)	(480)	(2,020)	(40.000)	(42.044)
Cash flow from financing	(12,900)	(5,600)	(15,420)	(12,862)	(13,911)
Chg in cash & cash eq.	1,510	(60)	700	(863)	2,626
Closing cash & cash eq.	2,760	2,070	2,280	1,417	4,043

Per Share	FY22A	FY23A	FY24A	FY25E	FY26E
Y/E 31 Mar (Rs) Reported EPS	9.5	10.1	11.5	12.6	13.7
Adjusted EPS	9.5	10.1	11.5	12.6	13.7
Dividend per share	9.5	4.7	9.5	9.5	10.3
Book value per share	26.4	30.7	32.3	35.6	39.2
book value per share	20.4	30.7	32.3	33.0	39.2
Valuations Ratios					
Y/E 31 Mar (x)	FY22A	FY23A	FY24A	FY25E	FY26E
EV/Sales	8.3	8.1	8.2	7.5	6.8
EV/EBITDA	47.2	43.9	39.2	35.3	32.8
Adjusted P/E	64.8	61.0	53.6	48.8	44.9
P/BV	23.3	20.1	19.0	17.3	15.7
DuPont Analysis					
Y/E 31 Mar (%)	FY22A	FY23A	FY24A	FY25E	FY26E
Tax burden (Net profit/PBT)	76.5	74.7	76.5	76.0	76.0
Interest burden (PBT/EBIT)	103.8	105.3	103.7	104.1	104.1
EBIT margin (EBIT/Revenue)	16.2	17.0	19.4	19.4	19.1
Asset turnover (Rev./Avg TA)	164.4	140.6	130.1	136.9	137.8
Leverage (Avg TA/Avg Equity)	1.7	1.8	1.8	1.7	1.7
Adjusted ROAE	36.0	32.9	35.5	35.4	34.9
Ratio Analysis	=1/004	=1/00.1	=>/0.4.4	=>/===	=>/20=
Y/E 31 Mar	FY22A	FY23A	FY24A	FY25E	FY26E
YoY growth (%)	40.0		(4.4)	40.4	
Revenue	18.2	2.6	(1.1)	10.1	9.8
EBITDA	5.7	7.7	11.9	10.9	7.8
Adjusted EPS	4.5	6.3	13.7	9.9	8.6
	4.5	0.0			
Profitability & Return ratios (%)					
EBITDA margin	17.7	18.5	21.0	21.2	
EBITDA margin EBIT margin	17.7 16.2	18.5 17.0	19.4	19.4	19.1
EBITDA margin EBIT margin Adjusted profit margin	17.7 16.2 12.9	18.5 17.0 13.3	19.4 15.3	19.4 15.3	19.1 15.2
EBITDA margin EBIT margin Adjusted profit margin Adjusted ROAE	17.7 16.2 12.9 36.8	18.5 17.0 13.3 35.4	19.4 15.3 36.5	19.4 15.3 37.1	19.1 15.2 36.6
EBITDA margin EBIT margin Adjusted profit margin Adjusted ROAE ROCE	17.7 16.2 12.9	18.5 17.0 13.3	19.4 15.3	19.4 15.3	19.1 15.2 36.6
EBITDA margin EBIT margin Adjusted profit margin Adjusted ROAE ROCE Working capital days (days)	17.7 16.2 12.9 36.8 30.9	18.5 17.0 13.3 35.4 28.0	19.4 15.3 36.5 28.0	19.4 15.3 37.1 28.2	19.1 15.2 36.6 28.1
EBITDA margin  EBIT margin  Adjusted profit margin  Adjusted ROAE  ROCE  Working capital days (days)  Receivables	17.7 16.2 12.9 36.8 30.9	18.5 17.0 13.3 35.4 28.0	19.4 15.3 36.5 28.0	19.4 15.3 37.1 28.2	19.1 15.2 36.6 28.1
EBITDA margin  EBIT margin  Adjusted profit margin  Adjusted ROAE  ROCE  Working capital days (days)  Receivables  Inventory	17.7 16.2 12.9 36.8 30.9	18.5 17.0 13.3 35.4 28.0	19.4 15.3 36.5 28.0 39 98	19.4 15.3 37.1 28.2 39 99	20.8 19.1 15.2 36.6 28.1
EBITDA margin  EBIT margin  Adjusted profit margin  Adjusted ROAE  ROCE  Working capital days (days)  Receivables  Inventory  Payables	17.7 16.2 12.9 36.8 30.9	18.5 17.0 13.3 35.4 28.0	19.4 15.3 36.5 28.0	19.4 15.3 37.1 28.2	19.1 15.2 36.6 28.1
EBITDA margin  EBIT margin  Adjusted profit margin  Adjusted ROAE  ROCE  Working capital days (days)  Receivables  Inventory  Payables  Ratios (x)	17.7 16.2 12.9 36.8 30.9 20 85 83	18.5 17.0 13.3 35.4 28.0 31 90	19.4 15.3 36.5 28.0 39 98 117	19.4 15.3 37.1 28.2 39 99 105	19.1 15.2 36.6 28.1 40 100
EBITDA margin  EBIT margin  Adjusted profit margin  Adjusted ROAE  ROCE  Working capital days (days)  Receivables  Inventory  Payables	17.7 16.2 12.9 36.8 30.9	18.5 17.0 13.3 35.4 28.0	19.4 15.3 36.5 28.0 39 98	19.4 15.3 37.1 28.2 39 99	19.1 15.2 36.6 28.1 40

Adjusted debt/equity 10.1 12.0

Source: Company, BOBCAPS Research | Note: TA = Total Assets

1.6

39.5

1.6

29.6

1.6

25.6

9.2

1.9

31.6

8.3

2.0

34.3

7.6

Current ratio

Net interest coverage ratio



NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA ("US") OR IN OR INTO ANY OTHER JURISDICTION IF SUCH AN ACTION IS PROHIBITED BY APPLICABLE LAW.

## **Disclaimer**

Name of the Research Entity: BOB Capital Markets Limited

Registered office Address: 1704, B Wing, Parinee Crescenzo, G Block, BKC, Bandra East, Mumbai 400051

SEBI Research Analyst Registration No: INH000000040 valid till 03 February 2025

Brand Name: BOBCAPS

Trade Name: www.barodaetrade.com CIN: U65999MH1996GOI098009





Investments in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

#### Recommendation scale: Recommendations and Absolute returns (%) over 12 months

BUY - Expected return >+15%


HOLD - Expected return from -6% to +15%

SELL - Expected return <-6%

Note: Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

#### Ratings and Target Price (3-year history): MARICO (MRCO IN)



 $B-Buy,\,H-Hold,\,S-Sell,\,A-Add,\,R-Reduce$ 

### Analyst certification

The research analyst(s) authoring this report hereby certifies that (1) all of the views expressed in this research report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOB Capital Markets Limited (BOBCAPS).

#### General disclaimers

BOBCAPS is engaged in the business of Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. BOBCAPS research reports follow rules laid down by Securities and Exchange Board of India and individuals employed as research analysts are separate from other employees who are performing sales trading, dealing, corporate finance advisory or any other activity that may affect the independence of its research reports.

### **MARICO**



The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

#### Company-specific disclosures under SEBI (Research Analysts) Regulations, 2014

The research analyst(s) or his/her relatives do not have any material conflict of interest at the time of publication of this research report.

BOBCAPS or its research analyst(s) or his/her relatives do not have any financial interest in the subject company. BOBCAPS or its research analyst(s) or his/her relatives do not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

The research analyst(s) has not received any compensation from the subject company or third party in the past 12 months in connection with research report/activities. Compensation of the research analyst(s) is not based on any specific merchant banking, investment banking or brokerage service transactions.

BOBCAPS or its research analyst(s) is not engaged in any market making activities for the subject company

The research analyst(s) has not served as an officer, director or employee of the subject company

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

BOBCAPS and MAYBANK (as defined below) make no representation or warranty, express or implied, as to the accuracy or completeness of any information obtained from third parties and expressly disclaim the merchantability, suitability, quality and fitness of this report. The information in this report has not been independently verified, is provided on an "as is" basis, should not be relied on by you in connection with any contract or commitment, and should not be used as a substitute for enquiries, procedures and advice which ought to be undertaken by you. This report also does not constitute an offer or solicitation to buy or sell any securities referred to herein and you should not construct his report as investment advice. All opinions and estimates contained in this report constitute BOBCAPS's judgment as of the date of this report and are subject to change without notice, and there is no obligation on BOBCAPS or MAYBANK to update this report upon issuance. This report and the information contained herein may not be reproduced, redistributed, disseminated or copied by any means without the prior consent of BOBCAPS and MAYBANK.

To the full extent permitted by law neither BOBCAPS, MAYBANK nor any of their respective affiliates, nor any other person, accepts any liability howsoever arising, whether in contract, tort, negligence, strict liability or any other basis, including without limitation, direct or indirect, special, incidental, consequential or punitive damages arising from any use of this report or the information contained herein. By accepting this report, you agree and undertake to fully indemnify and hold harmless BOBCAPS and MAYBANK from and against claims, charges, actions, proceedings, losses, liabilities, damages, expenses and demands (collectively, the "Losses") which BOBCAPS and/or MAYBANK may incur or suffer in any jurisdiction including but not limited to those Losses incurred by BOBCAPS and/or MAYBANK as a result of any proceedings or actions brought against them by any regulators and/or authorities, and which in any case are directly or indirectly occasioned by or result from or are attributable to anything done or omitted in relation to or arising from or in connection with this report.

#### Distribution into the United Kingdom ("UK"):

This research report will only be distributed in the United Kingdom, in accordance with the applicable laws and regulations of the UK, by Maybank Securities (London) Ltd) ("MSL") who is authorised and regulated by the Financial Conduct Authority ("FCA") in the United Kingdom (MSL and its affiliates are collectively referred to as "MAYBANK"). BOBCAPS is not authorized to directly distribute this research report in the UK.

This report has not been prepared by BOBCAPS in accordance with the UK's legal and regulatory requirements.

This research report is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of MAYBANK as selected by MAYBANK solely at its discretion; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time (the "Order"), or (c) fall within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc. as mentioned in the stated Article) of the Order; (all such persons together being referred to as "relevant persons").

This research report is directed only at relevant persons and must not be acted on or relied on by any persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons.

The relevant person as recipient of this research report is not permitted to reproduce, change, remove, pass on, distribute or disseminate the data or make it available to third parties without the written permission of BOBCAPS or MAYBANK. Any decision taken by the relevant person(s) pursuant to the research report shall be solely at their costs and consequences and BOBCAPS and MAYBANK shall not have any liability of whatsoever nature in this regard.

#### No distribution into the US:

This report will not be distributed in the US and no US person may rely on this communication.

This report has been prepared in accordance with SEBI (Research Analysts) Regulations and not in accordance with local regulatory requirements of any other jurisdiction. In any other jurisdictions, this report is only for distribution (subject to applicable legal or regulatory restrictions) to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions by Maybank Securities Pte Ltd. (Singapore) and / or by any broker-dealer affiliate or such other affiliate as determined by Malayan Banking Berhad.

If the recipient of this report is not as specified above, then it should not act upon this report and return the same to the sender.

By accepting this report, you agree to be bound by the foregoing limitations